2023 was a year of substantial new evidence informing the utility of semaglutide in people with #heartdisease Will 2024 be as impressive? #diabetes #obesity nejm.org/doi/full/10.10…

The benefits of semaglutide #T2D in HFpEF do not appear to be strictly related to #weightloss and remain evident on top of SGLT2i (32.8%) and mineralocorticoid receptor antagonists (32.5%) nejm.org/doi/full/10.10…

Semaglutide is tied to functional benefits in patients with obesity-related heart failure and preserved ejection fraction who have type 2 diabetes. Lead author Dr. Mikhail Kosiborod discusses the clinical implications. jwat.ch/3PLhXCf #ACC24 Mikhail Kosiborod

NEW #ACC24 Featured CT Interview 💫Dr Mikhail Kosiborod discusses findings from the STEP HFpEF DM Trial.

📽️👉 tinyurl.com/4d9wxtcu

📊 #Semaglutide 2.4mg ⬇️HF-related symptoms and physical limitations, ⬆️weight loss and ⬆️exercise function in patients with obesity-related #HFpEF …

Original Article: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM) nej.md/3TPKpUC

American College of Cardiology #ACC24

Comparison of findings in STEP HFpEF and STEP HFpEF Diabetes

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - The Lancet thelancet.com/journals/lance…

Javed Butler The Lancet #ACC2024

🔥 THIS JUST IN 🔥

⁦Javed Butler⁩ ⁦Mikhail Kosiborod⁩

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - The Lancet thelancet.com/journals/lance…

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed dlvr.it/T59BJB

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC

#ACC24

Breaking🔥 STEP-HFpEF-DM 🔥

Semaglutide (vs placebo) leads to more weight loss, improved health status (KCCQ-CSS), increased walking distance, improved glycemic control, reduced inflammation (CRP), reduced natriuretic peptides, reduced HF hospitalizations, with favorable safety…

#ACC24 🔥 is going to be packed with people, science, networking, and no doubt a few shenanigans to keep it entertaining.

Saint Luke's Mid America Heart Institute Saint Luke's will be visible!

Numerous original science and invited presentations.

Mikhail Kosiborod John Spertus Brett Sperry, MD Stacy L Farr, PhD, MPH…

🔥 #ACC24 🔥 LBCT

STEP-HFpEF in T2DM

Questions: ⁉️

I wanna know about:

🍕weight loss
🏌️‍♂️KCCQ
🚶‍♀️walk distance

A1c, natriuretic peptides, inflammation

Mikhail Kosiborod
Saint Luke's Mid America Heart Institute
American College of Cardiology

Big news for all of us working to help our patients with obesity and cardiovascular disease.

First, label expansion by the FDA,

Now CMSGov will cover.

STEP-HFpEF-DM at American College of Cardiology LBCT on April 6th presented by Mikhail Kosiborod of Saint Luke's Mid America Heart Institute

usnews.com/news/health-ne…

New data in European Society of Cardiology Journals #EJHF from #DAPAHF & #DELIVER by Alexander Peikert

#SGLT2i dapagliflozin shows consistent protection against hospitalizations & death in HF and prior MI

Will #SGLT2i modify risk early after acute MI? Stay tuned for #EMPACTMI at #ACC24 !

onlinelibrary.wiley.com/doi/full/10.10…

Look forward to presenting the STEP-HFPEF Diabetes Trial main results at ACC 2024. These data will be an important contribution to the rapidly evolving field of obesity-related Heart Failure with Preserved Ejection Fraction.

Late Breakers Announced for ACC!

STEP-HFpEF-DM

Saturday April 6th

Mikhail Kosiborod
American College of Cardiology
Saint Luke's Mid America Heart Institute
Saint Luke's

Saint Luke's Mid America Heart Institute is proud to announce we randomized first patient in REDEFINE-HF, an international, randomized, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with HFmrEF/HFpEF.

classic.clinicaltrials.gov/ct2/show/NCT06…

Proud of Saint Luke's Mid America Heart Institute representation in 'most-read' articles of 2023 for JACC: Heart Failure.

Beta-blocker Use in HFmrEF/HFpEF led by Suzanne Arnold and including Michael Nassif and Tim Fendler.

jacc.org/doi/10.1016/j.…

STEP-HFpEF Design paper, led by Mikhail Kosiborod…

Happy Holidays from all of us at the CMCA! As we reflect on 2023, we are immensely proud of the work of our members and appreciate our many partners and collaborators focused on advancing cardiometabolic care. We wish you all a season filled with joy, peace, and good health.